By Fineline Cube 
Peijia Medical Ltd (HKG: 9996) announced completion of the first patient implant in the Early Feasibility Study (EFS) for its GeminiOne transcatheter edge‑to‑edge repair (TEER) system in the United States. The milestone marks Peijia’s entry into the US structural heart market with its next‑generation mitral valve repair technology.
Clinical Milestone
| Parameter | Detail |
|---|---|
| Study Type | Early Feasibility Study (EFS) |
| Location | United States |
| First Patient | Implanted April 2026 |
| Product | GeminiOne TEER system |
| Target Indication | Mitral regurgitation (MR) |
Device Innovation & Differentiation
- Design Feature: Unique structural design enabling smaller implant size and delivery profile
- Clinical Advantage: Reduced procedural complexity vs. incumbent TEER systems; potential for broader physician adoption and expanded patient eligibility
- Intellectual Property: Global patent applications filed for system design
- Competitive Position: Addresses size limitations of first‑generation TEER devices (e.g., Abbott MitraClip, Edwards Pascal)
Global Regulatory Progress
| Region | Status | Milestone Date |
|---|---|---|
| European Union | CE Mark certified | Feb 2026 |
| China | NMPA review ongoing | Registration accepted; under review |
| United States | EFS initiated | Apr 2026 (first patient) |
Market Context & Outlook
- Mitral Regurgitation Market: Global US$5‑7 billion annually; TEER segment growing 15‑20% CAGR as alternative to surgical repair
- US Opportunity: Largest single market (~40% of global TEER volume); EFS completion enables pivotal trial initiation and premarket approval (PMA) pathway
- CE Mark Leverage: EU commercial launch expected H2 2026, generating clinical data and revenue to support US regulatory submission
- China Synergy: NMPA approval anticipated 2027; domestic manufacturing cost advantages position for price‑competitive market entry vs. Abbott/Edwards
- Revenue Trajectory: Peak global sales potential estimated at US$300‑500 million by 2032, assuming 8‑12% TEER market share across US, EU, and China
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial progression, regulatory approvals, and commercial projections for GeminiOne. Actual results may differ due to risks including EFS outcomes, FDA regulatory requirements, competitive response from established TEER players, and reimbursement negotiations.-Fineline Info & Tech